Skip to content New The AI buying guide for BD&L executives — now available on demand Watch

VibeOne Due Diligence

Aggregate the data and evidence on any asset in one place. Surface its risks, frame the opportunity and understand how it is differentiated.
VibeOne · Due Diligence Live
The problem

Challenges with diligence today

Under pressure

Deals are competitive, so diligence has to move fast. The first team to a clear view gets to the deal table.

Too many documents

Non-confidential decks, VDRs and public databases all have to be found, read and reconciled.

Laborious and costly

Each review needs experts in every functional area, pulled away from their day-to-day work.

High stakes

A deal turns on a few risks and opportunities. The review has to get to the heart of them.

General AI can't help

General AI can't plug into VDRs, and misses the nuance of the risks and opportunities that make or break a deal.

The VibeOne difference

Faster answers, in one place, on your terms

First to the deal table

Review assets 8x faster and get to the deal table first. Reach a view on an asset while competing bidders are still working through the data room.

All the data in one place

Every source in one analysis, from public data to VDRs and subscription databases. Each finding links back to its source document.

Scale without added headcount

Screen more assets across more therapeutic areas with the same team. Use AI for the first-pass review and cut reliance on internal experts by 75%.

Validated by PhDs

Every analysis is built and cross-checked by Vibe Bio's PhD drug development team. VibeOne is trained to surface nuanced risks and opportunities, drawing on the experience of real drug developers.

Inside the analysis

Risk, differentiation and opportunity for every asset

Review the overall risk and how the asset compares with standard of care. Every dimension links to a deep dive, and gaps stay flagged as open items.

Overview Dimensions Differentiation Export
Overall risk
Low
ABC-482 is an allogeneic CAR-T cell therapy in Phase 1/2 for T-cell acute lymphoblastic leukemia. The next value inflection is the Phase 2 topline readout.
Dimension briefs
Biology / MoA Moderate risk
Based on 4 of 4 evaluated criteria.
Clinical Low risk
Based on 5 of 6 evaluated criteria.
Regulatory Low risk
Based on 3 of 4 evaluated criteria.
Safety / Toxicology Moderate risk
Based on 1 of 2 evaluated criteria.
Pre-clinical Not available
Open diligence item.
Competitive landscape Moderate risk
Based on 3 of 4 evaluated criteria.
Differentiation
Vs. standard of care
Efficacy Differentiated
Mechanism of action / target Differentiated
Modality Differentiated
Safety Not yet assessable
Route of administration Not differentiated
Differentiation

See how the asset compares with the competition

Get a snapshot of the asset against standard of care and individual pipeline competitors, with a conclusion, the data table and a reference for every figure.

Overview Dimensions Differentiation Export
Conclusion
ABC-482 is differentiated from standard of care on response rate and mechanism. Against pipeline CD7 CAR-T programs, its advantage is off-the-shelf supply rather than response rate.
Attribute ABC-482 Allogeneic CAR-T · Ph 1/2 Standard of care Salvage chemo, then HSCT Competitor A Autologous CAR-T · Ph 2 Competitor B Anti-CD38 antibody · Ph 2
Target CD7 [1] Non-targeted [2] CD7 [3] CD38 [4]
Complete response 78% (n=23) [1] 31–36% [2] 85% (n=40) [3] 41% (n=27) [4]
Time to treatment Off the shelf [1] Immediate [2] 4–6 weeks manufacturing [3] Off the shelf [4]
Dosing Single IV infusion [1] Multi-cycle IV [2] Single IV infusion [3] IV every 2 weeks [4]
ABC-482 vs. comparator — Differentiated Partly differentiated Differentiated
[1] Data room: Phase 1/2 interim clinical study report
[2] Published Phase 2 data in relapsed/refractory T-ALL
[3] Company disclosure and conference abstract
[4] Trial registry record and conference poster
Case study · OTXL · CGTxchange

Diligencing assets at scale to accelerate BD deals

Nonprofit biotech accelerator. CGTxchange is its marketplace for clinical-stage cell and gene therapy programs.

The problem

Pharma & investors are looking for assets, but are uncertain which programs on the marketplace are worth it.

What VibeOne did

VibeOne Due Diligence analyzed the data room for every asset listed on the marketplace using a rigorous set of criteria to help buyers find the best assets.

The impact

OTXL adopted VibeOne as the standard for every CGTxchange listing.

6
Factors profiled on every listing
10,000+
Rare diseases in scope

Find your next asset with confidence.

See the evidence, the gaps, and how it compares.